The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19

Conditions

COVID-19, Azvudine

Brief summary

To establish a real-world clinical cohort and database of Azvudine in the treatment of SARS-CoV-2 infection, and to provide stable and reliable evidence for the clinical efficacy and safety evaluation of azvudine in the treatment of SARS-CoV-2 infection.

Fuwei Wang, Bohan Jia, Guotao Li, Xiaoli Jin, Mengzhao Yang et al. (15 authors)

BMJ Open2025-06-01

10.1136/bmjopen-2024-090230

Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases.

Su G, Gao F, Yang M, Wang L, Liang L, Li S, Li G, Han N, Li G, Qian G, Zhang S, Luo H, Zhang D, Liang H, Ren Z.

2025-05-19

10.1186/s12985-025-02771-1

The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease based on a multicenter retrospective cohort study

Bo Yu, Mengzhao Yang, Jia Xin Yu, Daming Wang, Hong Luo et al. (14 authors)

View2025-04-09

10.1002/viw.20240075

The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study

Junyi Sun, Mengzhao Yang, Guanyue Su, Ling Wang, Xiaobo Hu et al. (19 authors)

Advanced Science2025-02-22

10.1002/advs.202405679

Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study

Junyi Sun, Mengzhao Yang, Daoke Yao, Yongjian Zhou, Xiaobo Hu et al. (18 authors)

View2025-02-05

10.1002/viw.20240133

Real-world effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 infection: A multicenter, retrospective cohort study.

Ren Z, Yang M, Su G, Qian G, Yuan Y, Yu J, Li S, Wang C, Lu M, Luo H, Zhang S, Li G, Zhang D, Wang L, Li G, Jin X, Wang J, Wang M, Cheng M, Wang H, Chang J, Yu Z.

2024-11-172 citations

10.1016/j.jinf.2024.106355

Interventions

DRUGAzvudine

Antiviral drug

DRUGPaxlovid

Antiviral drug

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

1. Age above 18 years old (including the cut-off value), regardless of gender; 2. Patients diagnosed with 2019-ncov infection according to the diagnostic criteria of the latest edition of the Diagnosis and Treatment Plan for 2019-ncov Pneumonia issued by the Health Commission of China; 3. Informed consent has been signed.

Exclusion criteria

1. Known or suspected allergic to the components of Azivudine tablets; 2. Patients with severe liver, kidney, heart and other organ damage; 3. Pregnant or lactating women who planned to give birth during or within 6 months after the trial; 4. Had participated in other clinical trials or were using investigational drugs within 12 weeks before medication;

Design outcomes

Primary

Measure	Time frame	Description
All-cause death	Up to 30 days (form the date of confirmed COVID-19)	All-cause death was ascertained by electronic medical records.

Secondary

Measure	Time frame	Description
Composite disease progression	Up to 30 days (form the date of confirmed COVID-19)	Disease progression is defined as the occurrence of death, progression to severe or critical disease in mild or moderate patients, and the occurrence of death, progression to critical disease in severe patients. Severe disease is defined as respiratory rate ≥ 30 times/minute, or resting oxygen saturation ≤ 93%, or PaO2/FiO2 ≤ 300 mmHg, or lung lesions progressing \>50% at 24-48 hours. Critical disease is defined as the need for mechanical ventilation, or shock, or ICU monitoring.

Countries

China

Outcome results

None listed